04:27:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2024-03-21 12:30:31

Copenhagen, Denmark, 21 March 2024 - today Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

Today, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda:

1. The Board of Directors' report on the Company's activities in the preceding financial year

The general meeting toke note of the Board of Directors' report on the Company's activities in 2023.

2. Presentation and approval of the annual report

The general meeting adopted the Company's annual report for 2023 unanimously with all votes represented at the general meeting.

3. Appropriation of profit or covering of loss as recorded in the adopted annual report

The general meeting adopted the proposal to carry forward the result for 2023 to the next year according to the adopted annual report for 2023 with all votes represented at the general meeting.

4. Election of members to the Board of Directors

The general meeting re-elected Per Falholt, Lars Trolle, Kirsten Aarup Drejer, Charlotte Vedel, Andreas Kjaer and Ulrich Krasilnikoff as members of the Board of Directors with consent of all votes represented at the general meeting.

5. Election of auditor

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor with consent of all votes represented at the general meeting.

6. Proposed resolutions, if any, from the Board of Directors and/or the shareholders of the Company.

6.1 Authorisations to the Board of Directors to increase the Company's share      capital

A proposal from the Board of Directors to amend and extend the authorizations in the Company's Articles of Association was unanimously adopted with all votes represented at the general meeting. Consequently, the Company's Articles of Association will be updated to incorporate the following new sections:

5 Bemyndigelser Authorisations
5.1 Bemyndigelser til Authorisations to increase of the share
forhøjelse af capital
aktiekapitalen
5.1.1 Selskabets Until and including 21 March 2028, the
bestyrelse er board of directors shall be authorised to
bemyndiget til i increase the Company's share capital in
perioden til og one or more issues by up to a total
med 21. marts 2028 nominal amount of DKK 298,408.365 shares.
ad en eller flere Capital increases must be paid up in full
gange at forhøje in cash with pre-emption right for the
selskabets company's existing shareholders at a
aktiekapital med price determined by the board of
op til i alt directors, which may be below market
nominelt kr. price at the time of the decision of the
298.408,365 board of directors.
aktier.
Kapitalforhøjelser
skal ske ved fuld
kontant betaling
og med
fortegningsret for
selskabets
eksisterende
aktionærer til en
kurs fastsat af
bestyrelsen, der
kan være under
markedskursen på
tidspunktet for
bestyrelsens
beslutning.
5.1.2 Selskabets Until and including 21 March 2028, the
bestyrelse er board of directors shall be authorised to
bemyndiget til i increase the Company's share capital in
perioden til og one or more issues by up to a total
med 21. marts 2028 nominal amount of DKK 298,408.365 shares.
ad en eller flere Capital increases may be carried out by
gange at forhøje payment in full of cash contribution, in
selskabets -kind contribution of assets other than
aktiekapital med cash (contribution in kind) or through
op til i alt conversion of debt or a combination
nominelt kr. thereof. Capital increases shall be
298.408,365 effected at a price to be determined by
aktier. the board of directors, which may be
Kapitalforhøjelser below market price at the time of the
kan ske ved fuld decision of the board of directors, and
kontant betaling, without pre-emption right for the
ved indbetaling af existing shareholders.
andre værdier end
kontanter
(apportindskud)
eller ved
konvertering af
gæld eller som en
kombination heraf.
Kapitalforhøjelser
skal ske til en
kurs, der
fastsættes af
bestyrelsen, der
kan være under
markedskursen på
tidspunktet for
bestyrelsens
beslutning, og
skal ske uden
fortegningsret for
selskabets
eksisterende
aktionærer.
5.1.3 Bemyndigelserne i The authorisations set out in articles
pkt. 5.1.1 og 5.1.1 and 5.1.2 cannot, in the aggregate,
5.1.2 kan exceed a nominal amount of DKK
tilsammen ikke 298,408.365 shares.
overstige nominelt
kr. 298.408,365
aktier.
5.1.4 For de nye aktier New shares issued in accordance with
udstedt i henhold article 5.1.1 and/or article 5.1.2 shall
til pkt. 5.1.1 be subject to the same terms as the
og/eller 5.1.2 existing shares in the Company. The
skal gælde de shares shall be issued in the name of the
samme vilkår som shareholder, recorded in the name of the
for de shareholder in the Company's
eksisterende shareholders' register and shall be
aktier i negotiable instruments. The shares shall
Selskabet. be subject to the same rules on pre
Aktierne skal -emption rights, voting rights and
udstedes på navn, redeemability as the existing shares. The
skal noteres på new shares shall confer on the
navn i selskabets shareholder a right to receive dividends
ejerbog og skal and other rights and privileges in the
være Company as from the date of registration
omsætningspapirer. with the Danish Business Authority.
Aktierne skal være
underkastet de
samme regler om
fortegningsret,
stemmeret og
indløselighed som
de eksisterende
aktier. De nye
aktier skal give
aktionæren ret til
udbytte og andre
rettigheder i
Selskabet fra
tidspunktet for
registrering i
Erhvervsstyrelsen.
(As the
Articles of
Association
are available
in a Danish
and an
English
version it
should be
noted that
the Danish
version is to
prevail in
case of any
discrepancies
between the
two
versions.)

1. 6.2 Authorisation to the chairman of the meeting

The general meeting adopted a resolution to authorise the chairman of the meeting Rasmus Schou Pedersen to apply for registration of the resolutions passed and to make certain amendments, if necessary.

***

The Company's new articles of association will be published on the Company's website once they have been registered with the Danish Business Authority, and likewise, the minutes of the Annual General Meeting will also be made available on the website.

At a board meeting held immediately after the Annual General Meeting, Per Falholt was re-elected as chairman and Lars Trolle vice-chairman of the Board of Directors.